Narrow search
Showing 21 - 30 of 35,816
Cover Image
Measuring the Effects of Medication Use on Health-Related Quality of Life in Patients with Rheumatoid Arthritis: A Review
Nichol, Michael B.; Harada, Ann S. M. - In: PharmacoEconomics 16 (1999) 5, pp. 433-448
As the treatment of rheumatoid arthritis (RA) moves towards earlier and more consistently maintained therapy, often with highly toxic medications, the importance of assessing patients' health-related quality of life (HR-QOL) is of increasing concern to healthcare providers, insurers and...
Persistent link: https://www.econbiz.de/10005590298
Cover Image
Adalimumab for Rheumatoid Arthritis: Considerations for Reimbursement by Third-Party Payors
van de Putte, Leo; Nichol, Michael B. - In: Disease Management and Health Outcomes 12 (2004) 1, pp. 1-8
antagonists - infliximab, etanercept, and the most recently approved, adalimumab - address the limitations of traditional DMARDs … direct cost of care. Traditional disease-modifying antirheumatic drugs (DMARDs) [such as methotrexate and gold] have limited … the Monoclonal Antibody Adalimumab in Rheumatoid Arthritis, DE019 and DE011) indicate that adalimumab provides a rapid …
Persistent link: https://www.econbiz.de/10005448938
Cover Image
Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel Disease
Priest, Virginia L.; Begg, Evan J.; Gardiner, Sharon J.; … - In: PharmacoEconomics 24 (2006) 8, pp. 767-781
Objectives: To compare the cost effectiveness of azathioprine (AZA), methotrexate (MTX) and no immunosuppression for …
Persistent link: https://www.econbiz.de/10005404989
Cover Image
Understanding the Relationship between the EQ-5D, SF-6D, HAQ and Disease Activity in Inflammatory Arthritis
Adams, Roisin; Walsh, Cathal; Veale, Douglas; … - In: PharmacoEconomics 28 (2010) 6, pp. 477-487
Background: The growth of economic analyses and in particular cost-utility analyses (CUA), which use the QALY as a measure of outcome, has heightened the interest in the methodologies used to calculate the QALY. The EQ-5D has produced quite different utility values from that of the SF-6D. This...
Persistent link: https://www.econbiz.de/10008467351
Cover Image
Economic Evaluation of Etoricoxib versus Non-Selective NSAIDs in the Treatment of Osteoarthritis and Rheumatoid Arthritis Patients in the UK
Moore, Andrew; Phillips, Ceri; Hunsche, Elke; … - In: PharmacoEconomics 22 (2004) 10, pp. 643-660
Introduction: The objective of this study was to evaluate the potential economic implications of using etoricoxib versus non-selective NSAID alternatives in the treatment of patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in the UK. Study design: Decision-analytical modelling was...
Persistent link: https://www.econbiz.de/10005449127
Cover Image
Economic Burden of Psoriatic Arthritis
Ackermann, Christoph; Kavanaugh, Arthur - In: PharmacoEconomics 26 (2008) 2, pp. 121-129
Psoriatic arthritis (PsA) is a chronic autoimmune disease characterized by inflammatory arthritis in association with skin psoriasis (Ps). PsA may show a heterogeneous and variable clinical course, with involvement of peripheral and axial diarthrodial joints, periarticular structures such as...
Persistent link: https://www.econbiz.de/10005404900
Cover Image
Treatment of Atopic Dermatitis and Impact on Quality of Life: A Review with Emphasis on Topical Non-Corticosteroids
Schiffner, Roman; Schiffner-Rohe, Julia; Landthaler, Michael - In: PharmacoEconomics 21 (2003) 3, pp. 159-179
Atopic dermatitis (AD) is a chronic skin disease with increasing prevalence and rising costs. Stigmatisation and pruritus are only some aspects of potential quality-of-life (QOL) impairments. AD is not curable and repeated treatments are often necessary. At present, treatment with...
Persistent link: https://www.econbiz.de/10005449047
Cover Image
Q-TWiST Analysis of Cyclophosphamide, Epirubicin, Fluorouracil versus Cyclophosphamide, Methotrexate, Fluorouracil Treatment for Premenopausal Women with Node-Positive Breast Cance...
Radice, Davide; Redaelli, Alberto - In: PharmacoEconomics 23 (2005) 1, pp. 69-75
, methotrexate, and fluorouracil (CMF), using data from a phase III clinical trial (National Cancer Institute of Canada Clinical …
Persistent link: https://www.econbiz.de/10005404873
Cover Image
Economic Comparison of Leflunomide and Methotrexate in Patients with Rheumatoid Arthritis: An Evaluation Based on a 1-Year Randomised Controlled Trial
Maetzel, Andreas; Strand, Vibeke; Tugwell, Peter; … - In: PharmacoEconomics 20 (2002) 1, pp. 61-70
rheumatoid arthritis randomised to receive leflunomide, methotrexate or placebo during a 12-month period. Design and setting …) rating scale values and SG utilities, respectively, for leflunomide, methotrexate and placebo were 67.7 (18.0), 64.8 (18 ….1) and 57.5 (9.2), and 80.2 (22.1), 83.2 (18.0) and 77.0 (20.5). Both leflunomide and methotrexate had higher rating scale …
Persistent link: https://www.econbiz.de/10005405010
Cover Image
Work Productivity and Healthcare Resource Utilization Outcomes for Patients on Etanercept for Moderate-to-Severe Plaque Psoriasis: Results from a 1-Year, Multicentre, Open-Label, S...
Vender, Ronald; Lynde, Charles; Ho, Vincent; Chau, Dina; … - In: Applied Health Economics and Health Policy 10 (2012) 5, pp. 343-353
Background:Background: Data investigating the effect of etanercept on work productivity and healthcare resource … describe work productivity and healthcare resource utilization in patients with psoriasis prescribed etanercept. Abstract …-to-severe plaque psoriasis at baseline (Physician Global Assessment [PGA] ≥3, scale 0-5); able to start etanercept therapy as …
Persistent link: https://www.econbiz.de/10010567016